Sage Therapeutics Inc (SAGE)

Precedente Chiudi:

$12.01

Aprire:

$11.92

Volume 24 ore:

928.71K

Capitalizzazione di mercato:

$704.13M

Reddito:

$91.06M

Utile/perdita netta:

$-503.14M

Rapporto P/E:

-1.1794

EPS:

-9.92

Flusso di cassa netto:

$-424.74M

1 W Prestazione:

-1.68%

1M Prestazione:

-6.92%

6M Prestazione:

-38.94%

1 anno Prestazione:

-77.65%

Intervallo 1D:

$11.67

$12.04

Portata 52W:

$10.92

$59.99

Sage Therapeutics Inc Stock (SAGE) Company Profile

Nome

Sage Therapeutics Inc

Settore

Healthcare (1209)

Industria

Biotechnology (699)

Telefono

617-299-8380

Indirizzo

215 First Street, Cambridge, MA

Dipendente

257

Cinguettio

@SageBiotech

Prossima data di guadagno

2024-06-10

Ultimi documenti SEC

SAGE's Discussions on Twitter

Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-12	Iniziato	Deutsche Bank	Hold
2023-08-08	Downgrade	Canaccord Genuity	Buy → Hold
2023-08-08	Downgrade	Goldman	Buy → Neutral
2023-08-08	Downgrade	Needham	Buy → Hold
2023-08-07	Downgrade	BofA Securities	Buy → Neutral
2023-08-07	Downgrade	Oppenheimer	Outperform → Perform
2023-08-07	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2023-08-07	Downgrade	Stifel	Buy → Hold
2023-08-07	Downgrade	Wedbush	Outperform → Neutral
2023-07-27	Iniziato	Scotiabank	Sector Outperform
2023-03-13	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-01-03	Downgrade	Guggenheim	Buy → Neutral
2022-11-01	Iniziato	Loop Capital	Hold
2022-03-31	Iniziato	Berenberg	Hold
2021-11-02	Aggiornamento	Guggenheim	Neutral → Buy
2021-10-19	Ripresa	Morgan Stanley	Equal-Weight
2021-10-07	Downgrade	Jefferies	Buy → Hold
2021-09-23	Iniziato	Needham	Buy
2021-06-16	Downgrade	Citigroup	Buy → Neutral
2021-04-07	Iniziato	Piper Sandler	Overweight
2021-02-26	Downgrade	Mizuho	Buy → Neutral
2021-02-25	Reiterato	H.C. Wainwright	Neutral
2021-02-02	Ripresa	Raymond James	Mkt Perform
2021-01-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
2021-01-04	Aggiornamento	Guggenheim	Neutral → Buy
2021-01-04	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2020-12-04	Aggiornamento	Mizuho	Neutral → Buy
2020-12-01	Downgrade	Raymond James	Outperform → Mkt Perform
2020-11-16	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-11-06	Reiterato	H.C. Wainwright	Neutral
2020-09-11	Aggiornamento	Wedbush	Neutral → Outperform
2020-08-10	Aggiornamento	Raymond James	Mkt Perform → Outperform
2020-05-08	Downgrade	Wedbush	Outperform → Neutral
2020-04-08	Downgrade	Guggenheim	Buy → Neutral
2020-03-18	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2020-03-06	Iniziato	Citigroup	Buy
2020-02-28	Reiterato	H.C. Wainwright	Neutral
2020-02-06	Iniziato	Mizuho	Neutral
2019-12-06	Reiterato	RBC Capital Mkts	Outperform
2019-12-05	Reiterato	Guggenheim	Buy
2019-12-05	Downgrade	SunTrust	Buy → Hold
2019-10-30	Iniziato	H.C. Wainwright	Neutral
2019-05-23	Iniziato	Wedbush	Outperform
2019-04-25	Iniziato	Jefferies	Buy
2018-12-14	Iniziato	Wolfe Research	Outperform
2018-10-11	Iniziato	Oppenheimer	Outperform

Mostra tutto

Sage Therapeutics Inc Borsa (SAGE) Ultime notizie

Scotiabank Initiates Coverage of Sage Therapeutics (SAGE) with Sector Outperform Recommendation - MSN

MSN

Russell Investments Group Ltd. Buys 36827 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Defense World

Are Options Traders Betting on a Big Move in Sage Therapeutics (SAGE) Stock? - Yahoo News UK

Yahoo News UK

Sage Therapeutics Soars: Stock Adds 7.1% in Session - Yahoo News UK

Yahoo News UK

Los Angeles Capital Management LLC Acquires Shares of 15348 Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Defense World

What Makes Sage Therapeutics, Inc. (SAGE) a New Buy Stock - Yahoo News UK

Yahoo News UK

Sage Therapeutics Inc Azioni (SAGE) Dati Finanziari

Sage Therapeutics Inc (SAGE) Reddito 2024

Sage Therapeutics Inc (SAGE) Reddito netto 2024

Sage Therapeutics Inc (SAGE) Flusso di cassa 2024

Sage Therapeutics Inc (SAGE) Utile per azione 2024